The use of delta-tocotrienol and lovastatin for anti-osteoporotic therapy

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims Statins are competitive inhibitors of HMGCoA reductase and are commonly used as antihypercholesterolemic agents. Experimental studies clearly demonstrate the beneficial effects of statins on bone. Tocotrienols have also been shown to have anti-osteoporotic effects on the skeletal system. This study was conducted to observe the effect of a combination of delta-tocotrienol and lovastatin on structural bone histomorphometry and bone biomechanical strength in a postmenopausal rat model at clinically tolerable doses, and to compare it with the effect of delta-tocotrienol or lovastatin. Main methods Forty-eight female Sprague Dawley rats were randomly divided into six groups: baseline control; sham-operated control; ovariectomised control; ovariectomised + 11 mg/kg lovastatin; ovariectomised + 60 mg/kg delta-tocotrienol and ovariectomised + 60 mg/kg delta-tocotrienol + 11 mg/kg lovastatin. These treatments were given via oral gavage daily for eight weeks. After sacrificing the rats, the left and right femurs were dissected and processed for bone histomorphometric analysis and a bone biomechanical test, respectively. Key findings Delta-tocotrienol in combination with lovastatin significantly improved the trabecular volume, trabecular number, trabecular thickness and trabecular separation; and it significantly increased bone strength in oestrogen-deficient rats. Delta-tocotrienol alone enhanced bone formation and maintained bone strength in ovariectomised rats. Delta-tocotrienol plus lovastatin treatment promoted better trabecular volume and trabecular number and received higher load than delta-tocotrienol alone. Lovastatin alone was not effective. Significance Thus, the combination of delta-tocotrienol and lovastatin has the potential to be used for anti-osteoporotic therapy in postmenopausal women.

Original languageEnglish
Pages (from-to)42-48
Number of pages7
JournalLife Sciences
Volume125
DOIs
Publication statusPublished - 15 Mar 2015

Fingerprint

Lovastatin
Bone
Rats
Bone and Bones
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Tocotrienols
delta tocotrienol
Osteogenesis
Femur
Sprague Dawley Rats
Oxidoreductases
Estrogens
Control Groups

Keywords

  • Biomechanical test
  • Bone histomorphometry
  • Bone strength
  • HMGCoA reductase
  • Lovastatin
  • Osteoporosis
  • Ovariectomised
  • Postmenopausal women
  • Statins
  • Tocotrienols
  • Trabecular

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The use of delta-tocotrienol and lovastatin for anti-osteoporotic therapy. / Abdul-Majeed, Saif; Mohamed, Norazlina; Soelaiman, Ima Nirwana.

In: Life Sciences, Vol. 125, 15.03.2015, p. 42-48.

Research output: Contribution to journalArticle

@article{d81648047a8244a79d686ee7653bb347,
title = "The use of delta-tocotrienol and lovastatin for anti-osteoporotic therapy",
abstract = "Aims Statins are competitive inhibitors of HMGCoA reductase and are commonly used as antihypercholesterolemic agents. Experimental studies clearly demonstrate the beneficial effects of statins on bone. Tocotrienols have also been shown to have anti-osteoporotic effects on the skeletal system. This study was conducted to observe the effect of a combination of delta-tocotrienol and lovastatin on structural bone histomorphometry and bone biomechanical strength in a postmenopausal rat model at clinically tolerable doses, and to compare it with the effect of delta-tocotrienol or lovastatin. Main methods Forty-eight female Sprague Dawley rats were randomly divided into six groups: baseline control; sham-operated control; ovariectomised control; ovariectomised + 11 mg/kg lovastatin; ovariectomised + 60 mg/kg delta-tocotrienol and ovariectomised + 60 mg/kg delta-tocotrienol + 11 mg/kg lovastatin. These treatments were given via oral gavage daily for eight weeks. After sacrificing the rats, the left and right femurs were dissected and processed for bone histomorphometric analysis and a bone biomechanical test, respectively. Key findings Delta-tocotrienol in combination with lovastatin significantly improved the trabecular volume, trabecular number, trabecular thickness and trabecular separation; and it significantly increased bone strength in oestrogen-deficient rats. Delta-tocotrienol alone enhanced bone formation and maintained bone strength in ovariectomised rats. Delta-tocotrienol plus lovastatin treatment promoted better trabecular volume and trabecular number and received higher load than delta-tocotrienol alone. Lovastatin alone was not effective. Significance Thus, the combination of delta-tocotrienol and lovastatin has the potential to be used for anti-osteoporotic therapy in postmenopausal women.",
keywords = "Biomechanical test, Bone histomorphometry, Bone strength, HMGCoA reductase, Lovastatin, Osteoporosis, Ovariectomised, Postmenopausal women, Statins, Tocotrienols, Trabecular",
author = "Saif Abdul-Majeed and Norazlina Mohamed and Soelaiman, {Ima Nirwana}",
year = "2015",
month = "3",
day = "15",
doi = "10.1016/j.lfs.2014.12.012",
language = "English",
volume = "125",
pages = "42--48",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The use of delta-tocotrienol and lovastatin for anti-osteoporotic therapy

AU - Abdul-Majeed, Saif

AU - Mohamed, Norazlina

AU - Soelaiman, Ima Nirwana

PY - 2015/3/15

Y1 - 2015/3/15

N2 - Aims Statins are competitive inhibitors of HMGCoA reductase and are commonly used as antihypercholesterolemic agents. Experimental studies clearly demonstrate the beneficial effects of statins on bone. Tocotrienols have also been shown to have anti-osteoporotic effects on the skeletal system. This study was conducted to observe the effect of a combination of delta-tocotrienol and lovastatin on structural bone histomorphometry and bone biomechanical strength in a postmenopausal rat model at clinically tolerable doses, and to compare it with the effect of delta-tocotrienol or lovastatin. Main methods Forty-eight female Sprague Dawley rats were randomly divided into six groups: baseline control; sham-operated control; ovariectomised control; ovariectomised + 11 mg/kg lovastatin; ovariectomised + 60 mg/kg delta-tocotrienol and ovariectomised + 60 mg/kg delta-tocotrienol + 11 mg/kg lovastatin. These treatments were given via oral gavage daily for eight weeks. After sacrificing the rats, the left and right femurs were dissected and processed for bone histomorphometric analysis and a bone biomechanical test, respectively. Key findings Delta-tocotrienol in combination with lovastatin significantly improved the trabecular volume, trabecular number, trabecular thickness and trabecular separation; and it significantly increased bone strength in oestrogen-deficient rats. Delta-tocotrienol alone enhanced bone formation and maintained bone strength in ovariectomised rats. Delta-tocotrienol plus lovastatin treatment promoted better trabecular volume and trabecular number and received higher load than delta-tocotrienol alone. Lovastatin alone was not effective. Significance Thus, the combination of delta-tocotrienol and lovastatin has the potential to be used for anti-osteoporotic therapy in postmenopausal women.

AB - Aims Statins are competitive inhibitors of HMGCoA reductase and are commonly used as antihypercholesterolemic agents. Experimental studies clearly demonstrate the beneficial effects of statins on bone. Tocotrienols have also been shown to have anti-osteoporotic effects on the skeletal system. This study was conducted to observe the effect of a combination of delta-tocotrienol and lovastatin on structural bone histomorphometry and bone biomechanical strength in a postmenopausal rat model at clinically tolerable doses, and to compare it with the effect of delta-tocotrienol or lovastatin. Main methods Forty-eight female Sprague Dawley rats were randomly divided into six groups: baseline control; sham-operated control; ovariectomised control; ovariectomised + 11 mg/kg lovastatin; ovariectomised + 60 mg/kg delta-tocotrienol and ovariectomised + 60 mg/kg delta-tocotrienol + 11 mg/kg lovastatin. These treatments were given via oral gavage daily for eight weeks. After sacrificing the rats, the left and right femurs were dissected and processed for bone histomorphometric analysis and a bone biomechanical test, respectively. Key findings Delta-tocotrienol in combination with lovastatin significantly improved the trabecular volume, trabecular number, trabecular thickness and trabecular separation; and it significantly increased bone strength in oestrogen-deficient rats. Delta-tocotrienol alone enhanced bone formation and maintained bone strength in ovariectomised rats. Delta-tocotrienol plus lovastatin treatment promoted better trabecular volume and trabecular number and received higher load than delta-tocotrienol alone. Lovastatin alone was not effective. Significance Thus, the combination of delta-tocotrienol and lovastatin has the potential to be used for anti-osteoporotic therapy in postmenopausal women.

KW - Biomechanical test

KW - Bone histomorphometry

KW - Bone strength

KW - HMGCoA reductase

KW - Lovastatin

KW - Osteoporosis

KW - Ovariectomised

KW - Postmenopausal women

KW - Statins

KW - Tocotrienols

KW - Trabecular

UR - http://www.scopus.com/inward/record.url?scp=84923911970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923911970&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2014.12.012

DO - 10.1016/j.lfs.2014.12.012

M3 - Article

C2 - 25534439

AN - SCOPUS:84923911970

VL - 125

SP - 42

EP - 48

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -